Article

A Specific Marker for Detecting Bacterial Infection in RA

Serum procalcitonin level is a more specific marker for detection of bacterial infection in patients with rheumatoid arthritis than C-reactive protein level, erythrocyte sedimentation rate, or white blood cell count.

Serum procalcitonin (PCT) level is a more specific marker for detection of bacterial infection in patients with rheumatoid arthritis (RA) than C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), or white blood cell (WBC) count. High PCT levels (0.5 ng/mL or higher) strongly suggest bacterial infection, but a PCT level lower than 0.5 ng/mL does not rule it out.

Sato and colleagues studied 118 patients who experienced an RA flare, a noninfectious complication of RA or its treatment, a nonbacterial infection, or a bacterial infection. The PCT level was higher in the bacterial infection group than in the other 3 groups (25.8% vs 0% to 4.3%), and the difference was significant among groups. Conversely, no statistically significant difference was observed among the groups with a CRP concentration of 0.3 mg/dL or higher, WBC count higher than 8500/μL, or ESR higher than 15 mm/h. The specificity and positive likelihood ratio of a PCT level of 0.5 ng/mL or higher were highest for detection of bacterial infection, although the sensitivity was low.

The authors noted that RA is a chronic inflammatory disease accompanied by many complications and that serious infections are associated with many of the advanced therapeutics used to manage it.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.